Get the Stockscreener App
1.99
1.00%
-0.02
Sutro Biopharma Inc stock is traded at $1.99, with a volume of 912.33K.
It is down -1.00% in the last 24 hours and up +5.85% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
See More
Previous Close:
$2.01
Open:
$2.07
24h Volume:
912.33K
Relative Volume:
0.96
Market Cap:
$164.09M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-1.118
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
+15.70%
1M Performance:
+5.85%
6M Performance:
-47.14%
1Y Performance:
-50.99%
1-Day Range:
$1.905
$2.07
1-Week Range:
$1.72
$2.08
52-Week Range:
$1.67
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
1.99 | 164.09M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Growth in Short Interest - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Barclays PLC Acquires 216,757 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $1.7 amid market challenges - Investing.com Nigeria
Sutro Biopharma (NASDAQ:STRO) versus Sorrento Therapeutics (OTCMKTS:SRNEQ) Head-To-Head Comparison - Defense World
Jane Street Group LLC Acquires 25,416 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale - The Manila Times
Sutro Biopharma Achieves Breakthrough: Cell-Free Cancer Drug Production Scales to 4,500L - StockTitan
Great week for Sutro Biopharma, Inc. (NASDAQ:STRO) institutional investors after losing 42% over the previous year - Simply Wall St
Geode Capital Management LLC Has $6.43 Million Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless (NASDAQ:STRO) - Seeking Alpha
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Barclays PLC - Defense World
Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Expands By 19.4% - MarketBeat
State Street Corp Buys 81,855 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Consensus PT from Analysts - MarketBeat
Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Charles Schwab Investment Management Inc. Acquires 35,167 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $2.02 By Investing.com - Investing.com Canada
Fmr LLC Acquires 37,701 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $2.02 - Investing.com
BNP Paribas Financial Markets Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Novavax (NASDAQ:NVAX) and Sutro Biopharma (NASDAQ:STRO) Financial Review - Defense World
Sutro Biopharma's SWOT analysis: promising pipeline drives stock outlook - Investing.com
Wells Fargo & Company Lowers Sutro Biopharma (NASDAQ:STRO) Price Target to $4.00 - Defense World
Sutro Biopharma’s (STRO) Outperform Rating Reiterated at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Earns “Market Outperform” Rating from JMP Securities - Defense World
Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts - Benzinga
Sutro Biopharma stock hits 52-week low at $2.45 - Investing.com India
Sutro Biopharma stock hits 52-week low at $2.45 By Investing.com - Investing.com Canada
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - The Manila Times
Sutro's Luvelta Shows Promising 32% Response Rate in Ovarian Cancer Trial, Eyes FDA Fast Track - StockTitan
Intech Investment Management LLC Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Point72 Asset Management L.P. Decreases Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Jacobs Levy Equity Management Inc. Lowers Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Bank of Montreal Can Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (FRA:S09) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
Sutro Biopharma (FRA:S09) Enterprise Value : €-129.3 Mil (As of Dec. 04, 2024) - GuruFocus.com
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $12.14 - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Drop in Short Interest - MarketBeat
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge - Simply Wall St
Suvretta Capital Management LLC Sells 521,195 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $12.14 - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $1.51 Million in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (STU:S09) Enterprise Value : €-142.7 Mil (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma (STU:S09) Forward Dividend Yield % : 0.00% (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):